Debate: When should we intervene in unstable angina - Time for an old look? by Laskey, Warren K
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
Commentary
Debate: When should we intervene in unstable angina?
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Abstract
Current treatment modalities for patients with acute coronary syndromes center on early
diagnosis, risk stratification and, increasingly, early treatment including invasive approaches.
The appropriate timing of these invasive modalities in the context of the overall treatment
program remains an area of controversy. Specifically, studies in the past recommended a
period of medical ‘stabilization’ while current approaches are considerably more aggressive.
The potential hazard of early intervention, in particular, has not properly been weighed against
the benefit. This article hopes to provide a framework for examining the appropriate timing of
intervention, specifically percutaneous coronary intervention, in acute coronary syndromes.
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Introduction
The natural history of acute coronary syndromes (ACS),
formerly referred to as unstable angina, is characterized by
an early, high-risk period followed by a longer period of
diminishing risk, which ultimately is statistically indistin-
guishable from clinically stable coronary heart disease
[1,2]. Classic studies have now demonstrated important
effects of specific pharmacologic treatments for these
patients [3,4]. However, a disturbingly persistent rate of
death or myocardial infarction of 12.1% at 6 months [5],
and of 14.1% [6] and 12.2% [7] at 1 year, in conjunction
with an increasingly aggressive approach to patient man-
agement, has led to the present controversy over the
appropriate treatment of these patients. Specifically, the
widespread availability of invasive services (at least in the
USA) has accelerated the timing of invasive approaches
to patient management. While some of this compressed
care has been driven by third-party payors, a significant
component of what to do and when is at the discretion of
the physician. Therefore, a careful look at the time-honored
approach defined as ‘cooling off’ and the current
approach of ‘do-it-now’ is in order.
What is ‘cooling off?’
Our earlier concept of clinical quiescence was based on
eliminating the frequency of anginal episodes [8]. In the
early days of percutaneous transluminal coronary angio-
plasty (PTCA), now referred to as percutaneous coronary
intervention (PCI), ‘hot’ patients appeared to fare less well
with our efforts [9]. A period of ‘cooling off’ was thereforeCurrent Controlled Trials in Cardiovascular Medicine    Vol 1 No 1 Laskey
recommended by many prior to PCI [9]. This period was in
no way tantamount to benign neglect. The ‘cooling off’
period was defined, at that time, by state of the art antico-
agulant, antiplatelet and anti-ischemic therapy. We have
clearly learned much since these early studies. We now
know that ‘hot’ patients truly have an underlying patho-
physiology that has a strong inflammatory component
[10]. Moreover, the ‘hot’ plaque in these patients is char-
acterized by increased fragility [11], enhanced thrombo-
genicity [12,13], and cellular and molecular markers of
inflammation [14]. It is, in fact, the presence of these
inflammatory markers in the sera of these patients that
appears to correlate best with both short-term and long-
term clinical outcome [15,16]. Treatment programs
directed towards ‘cooling off’ these patients must thus
take into account this pathophysiology. The lessons
learned from prior studies of PCI in patients with ACS
have clearly provided a strong rationale for the current use
of potent antiplatelet and antithrombotic agents. It is
notable, however, that while specific anti-inflammatory
therapy (in contrast to anti-infection therapy) may not be
available at present, treatment programs that include an
aggressive approach to lipid lowering may confer signifi-
cant benefit [17]. The ‘anti-inflammatory’ sequelae of
antioxidant and lipid lowering therapies are not, in fact, to
be underestimated in their importance [18].
The past
Early studies, as has already been noted, reported higher
rates of adverse clinical events during PCI in patients with
ACS. Although subject to considerable bias as a conse-
quence of their retrospective nature, several studies did
suggest that a period of ‘stabilization’ resulted in improved
clinical outcomes [9]. Given the presence of angiographi-
cally evident thrombus within the culprit vessel in such
patients, algorithms were developed that included an
extended period of anticoagulation prior to PCI. Our group
reported improved procedural outcomes in patients with
unstable angina who received an extended period of intra-
venous heparin [19]. Importantly, a relatively well-defined
‘cut point’ was seen at 72 h [19]. It is also of note that this
time dependence of procedural success was seen in both
groups of patients (Fig. 1).
The present
The advent of potent pharmacologic adjuncts, for example
platelet glycoprotein IIb/IIIa receptor antagonists, and the
enhanced procedural safety offered by stents have dramat-
ically changed the current landscape. In lieu of any period
of ‘cooling down’, patients are now referred for invasive
coronary procedures with alacrity. The latter, coupled with
an ever-increasing trend in the performance of combined
diagnostic and interventional procedures, has resulted in
PCI being performed at a very early stage in the natural
history of ACS. It is during this early period that the hazard
of intervention is greatest [5,20]. Specifically, the marked
inflammatory response and liberation of cytokines [21], the
generation of free radicals [22], the enhanced activity of
both intrinsic and extrinsic pathways of coagulation [23],
and the perturbations in endothelial function that character-
ize both the active lesion and the response to mechanical
disruption [14] all contribute to this potential hazard.
Another issue, however, is now upon us: PCI itself is asso-
ciated with myocardial damage as reflected in postproce-
dural increases in myocardial-specific enzymes [24,25].
These measures of myocardial necrosis following PCI are
in fact found more frequently in the setting of ACS than in
more clinically stable populations [25]. While the etiology
of the postprocedural enzyme release remains speculative,
the possibility of distal thrombo-embolization consequent
to plaque disruption is strongly supported by the mitiga-
tion of these events with the use of platelet glycoprotein
IIb/IIIa receptor antagonists [26]. In virtually every recent
trial of PCI in the setting of ACS, the increase in postpro-
cedural CPK-MB fraction is several-fold greater than the
control (prePCI) rate [26]. A second hazard is thus appar-
ent, but whether this second hazard is disproportionately
increased in patients undergoing ‘early’ PCI compared
with a delayed procedure is unclear. An examination of the
outcomes following PCI in clinical trials in which patients
were randomized to either an ‘aggressive’ approach
versus a ‘conservative’ approach (TIMI III [7], VANQWISH
[27], FRISC-II [5]) or pharmacologic trials in which PCI
was deferred as a consequence of the duration of infusion
of the study drug (EPIC [20], CAPTURE [28], PURSUIT
[29], PRISM-PLUS [30]) provides some interesting
insights (Fig. 2).
Although these trials differed substantially in design, primary
end-points and pharmacologic adjuncts, the theme of early
Figure 1
Procedural success rates were significantly (P < 0.05) improved with a
preprocedural infusion of heparin for at least 48 h. Adapted from [19].
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versus deferred PCI is common to all. It can be seen that
there is a statistically significant (inverse) relationship
between short-term major adverse coronary events (MACE)
rates as reported in the individual trials and the timing of
intervention. Furthermore, it is of note that there is a 50%
reduction of this MACE rate when intervention is deferred
until at least 48 h following randomization.
Another look
It is important to point out that these opinions are neither
an indictment of the invasive approach to ACS nor
support for the conservative approach. They rather argue
for a period of ‘stabilization’ with appropriate treatment
and a treatment algorithm that emphasizes the appropriate
time for intervention. There is little question that ‘earlier is
better’ with respect to intervention in the setting of acute
myocardial infarction. However, important differences in
clinical, pathophysiologic, coronary anatomic and hemody-
namic features distinguish patients with non-ST-elevation
myocardial infarction from their more dramatic counter-
parts. It is suggested, in this article, that the ‘appropriate’
timing for PCI in the setting of ACS must consider the
early hazard of procedural-related myonecrosis, the short-
term and long-term consequences of procedural-related
increases in inflammatory markers and markers of the
thrombotic state, and, finally, the increasingly cogent evi-
dence in support of aggressive treatment of modifiable
risk factors. The only answer to this question is, as always,
a prospective randomized trial stratified by the timing of
PCI.
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